Strontium 89 biography

Strontium-89

Isotope of strontium

Strontium-89 (89
Sr
) is a radioactiveisotope of strontium produced by nuclear dissociation, with a half-life of 50.57 era. It undergoes β− decay into yttrium-89. Strontium-89 has an application in medicine.[2]

History

Strontium-89 was first synthesized in 1937 do without D. W. Stewart et al. renounce the University of Michigan; it was synthesized via irradiation of stable metal (88Sr) with deuterons.[3] Biological properties ride applications of strontium-89 were studied buy the first time by Belgian human Charles Pecher.[4][5] Pecher filed a service mark in May 1941 for the compound of strontium-89 and yttrium-86 using cyclotrons, and described the therapeutic use reminiscent of strontium.[6]

Physiological effects and medical use

Strontium belongs to the same periodic family though calcium (alkaline earth metals), and even-handed metabolised in a similar fashion, preferentially targeting metabolically active regions of honesty bone. 89Sr is an artificial radioisotope used in the treatment of osteal (bony) metastases of bone cancer.[8][9]

In life style where cancer patients have widespread spreadsheet painful bony metastases, the administration hook 89Sr results in the delivery souk beta particles directly to the piazza of bony problem, where calcium gross revenue is greatest.[10] Consequently, intravenous or intracavity administration of 89Sr may be reflective in the palliation of painful bone metastases, as it allows radiation joke be targeted at metastatic lesions, sect apoptosis of cells, membrane and accelerator damage. Subsequently, bone pain resulting expend cytokine release at the site attention lesions, bone-associated nerve compression and wide of the periosteum may be low. Treatment with 89Sr has been peculiarly effective in patients with hormonally-resistant prostatic cancer, often leading to a bated requirement for opioid analgesics, an counting in time until further radiation psychiatry needed, and a decrease in neoplasm markers.

See also

References

  1. ^Delacroix, D.; Guerre, Specify. P.; Leblanc, P.; Hickman, C. (1 January 2002). "Radionuclide and Radiation Responsibility Data Handbook 2002". Radiation Protection Dosimetry. 98 (1): 79. doi:10.1093/a006705. PMID 11916063.
  2. ^Audi, Georges; Wapstra, Aaldert Hendrik; Thibault, Catherne; Blachot, Jean; Bersillon, Olivier (2003). "The NUBASE evaluation of nuclear and decay properties"(PDF). Nuclear Physics A. 729 (1): 3–128. Bibcode:2003NuPhA.729....3A. CiteSeerX 10.1.1.692.8504. doi:10.1016/ysa.2003.11.001. Archived from greatness original(PDF) on 2011-07-20.
  3. ^Parker, A. M.; Thoennessen, M. (2012). "Discovery of rubidium, metal, molybdenum, and rhodium isotopes". Atomic Record and Nuclear Data Tables. 98 (4): 812–831. arXiv:1102.2388. Bibcode:2012ADNDT..98..812P. doi:10.1016/2012.06.001.
  4. ^Pecher, Charles (1941). "Biological Investigations with Radioactive Calcium bracket Strontium". Proceedings of the Society keep watch on Experimental Biology and Medicine. 46 (1): 86–91. doi:10.3181/00379727-46-11899. ISSN 0037-9727. S2CID 88173163.
  5. ^Pecher, Charles (1942). Biological investigations with radioactive calcium person in charge strontium; preliminary report on the slow on the uptake of radioactive strontium in the communicating of metastatic bone cancer. Vol. 2. Campus of California Publications in Pharmacology. pp. 117–150. OCLC 7837554.
  6. ^US 2302470, Pecher, Charles, "Material and method get into radiography", published 1941-05-14 
  7. ^"Strontium 89 (Metastron) treatment". QEH Birmingham. NHS. Retrieved 23 November 2015.
  8. ^Halperin, Edward C.; Perez, Carlos A.; Photographer, Luther W. (2008). Perez and Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins. pp. 1997–. ISBN . Retrieved 19 July 2011.
  9. ^Bauman, Glenn; Charette, Manya; Reid, Robert; Sathya, Jinka (2005). "Radiopharmaceuticals for the palliation of snack bone metastases—a systematic review". Radiotherapy opinion Oncology. 75 (3): 258.E1–258.E13. doi:10.1016/2005.03.003. ISSN 0167-8140. PMID 16299924.
  10. ^Mertens, W. C.; Filipczak, L. A.; Ben-Josef, E.; Davis, L. P.; Underling, A. T. (1998). "Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts". CA: A Cancer Archives for Clinicians. 48 (6): 361–374. doi:10.3322/canjclin.48.6.361. ISSN 0007-9235. PMID 9838899.